Transforming drug discovery through AI,
genomics and iPSCs
Greenstone Biosciences stands at the forefront of biotechnological innovation, combining the power of Artificial Intelligence (AI) and human induced Pluripotent Stem Cells (hiPSC) to revolutionize the drug discovery process.
Our mission is to accelerate the development of effective therapies for patients by harnessing our cutting-edge AI-hiPSC platform. This unique integration facilitates a more efficient, precise, and transformative approach to identifying potential therapeutic compounds, ultimately expediting the journey from laboratory research to patient care.
Greenstone Biosciences stands at the forefront of biotechnological innovation, combining the power of Artificial Intelligence (AI) and human induced Pluripotent Stem Cells (hiPSC) to revolutionize the drug discovery process. Our mission is to accelerate the development of effective therapies for patients by harnessing our cutting-edge AI-hiPSC platform. This unique integration facilitates a more efficient, precise, and transformative approach to identifying potential therapeutic compounds, ultimately expediting the journey from laboratory research to patient care.
Sign up now & get regular updates! News publications and news about drug discovery are waiting for you!
Fill out the form below!
We Are Greenstone
Our mission is transforming drug discovery and accelerating the development of effective therapies for patients.
The Largest hiPSC Biobank
Greenstone, situated at Stanford Research Park within the Alexandria Center for Life Sciences, is a multifaceted platform advancing drug discovery. Beyond computational biology, we house a comprehensive iPSC biobank, accelerating the development of effective therapies for patients.
follow our latest news
Greenstone scientists and collaborators regularly publish in peer-reviewed publications to inform the scientific community of discoveries from Greenstone labs and our collaborators.
Excited to share our latest commentary in Nature Reviews Drug Discovery! We delve into the challenges and advancements in using new approach methods for predicting drug effects from model systems. We focus on human-derived iPSCs and the integration of AI tools, and the field’s aim to enhance the accuracy and reliability of preclinical drug testing.
Tackling the challenges of new approach methods for predicting drug effects from model systems
Paul D.Pang, Syed Mukhtar Ahmed, Masataka Nishiga, Norman L Stockbridge, Joseph C Wu
Greenstone Biosciences is a proud sponsor of the 2024 Stanford Drug Discovery Symposium that was held at Stanford between April 29-30.